Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04645147
Recruitment Status : Recruiting
First Posted : November 27, 2020
Last Update Posted : September 17, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:

Background:

Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Up to 1 in 10 people who get mono can have fatigue that lasts more than 6 months. One out of 100 people can have severe complications. EBV is also associated with several types of cancer. Researchers want to test an EBV vaccine.

Objective:

To test the safety of and immune response to a new vaccine against EBV.

Eligibility:

Healthy adults ages 18-29

Design:

Participants will be screened with a medical history and physical exam. They will give a blood sample.

Screening tests will be repeated during the study.

Participants will get a dose of the study vaccine as an injection in a muscle in the upper arm. They will be observed for 30 to 60 minutes. Blood pressure, heart rate, breathing rate, and temperature will be checked. The injection site will be examined.

Participants will get a diary card. They will write down any side effects they have after the vaccine dose, or they may use an electronic diary card. Participants will be asked to write down or enter any important medical events that may occur at any time during the study.

Participants will get a vaccine dose at 2 more study visits. They will have 4 follow-up visits at different times after a vaccine dose.

Participants will have 6 telephone calls in between the in-person visits. They will also have 1 telephone call 1 year after the third dose of vaccine. If possible, this visit can occur in person.

Participation will last about 18 months. There is an optional in-person visit or telephone call 2 years after the third dose of vaccine.


Condition or disease Intervention/treatment Phase
EBV Epstein-Barr Virus Infection Infectious Mononucleosis Biological: EBV gp350-Ferritin Vaccine Other: Matrix-M1 Phase 1

Detailed Description:

This is a phase 1, open-label study to evaluate the safety and immunogenicity of an Epstein-Barr virus (EBV) gp350-Ferritin nanoparticle vaccine adjuvanted with Matrix-M1. Forty healthy volunteers will be enrolled and dosed in this trial: 20 EBV seropositive participants and 20 EBV seronegative. Each participant will receive 3 intramuscular doses of vaccine on Days 0, 30, and 180. Follow-up visits will occur after each dose of vaccine either in person or by telephone contact. In addition to vaccine dosing days, mandatory in-person visits will occur in the first week after the first dose of vaccine, 1 month after the second and third doses of vaccine, and 6 months after the third dose of vaccine. The primary endpoint is assessment of safety and includes solicited injection site and systemic reactions related to vaccination that occur in the 7-day period after each vaccination, unsolicited adverse events occurring up to 30 days after each vaccination, and serious adverse events through 1 year after the third dose of vaccine. A mandatory telephone, optional in-person, contact will occur 1 year after the third dose of vaccine (Day 540) to collect information about medically attended events and significant new medical conditions to assess for possible autoimmune disease that may be related to the adjuvant, Matrix-M1. An optional visit may occur 2 years after the third dose of vaccine (Day 900) to collect similar medical information and possibly assess durability of immune responses to vaccination. The primary endpoint for immunogenicity is the change in log10 antibody responses to EBV from baseline to 1 month after the third vaccine dose as measured by an neutralization assay. Secondary immunogenicity endpoints are the change in log10 antibody responses to

EBV gp350 from baseline to 1 month after the third vaccine dose as measured by a luciferase immunoprecipitation assay and the change in log10 CD4 T cell responses to EBV gp350 from baseline to 1 month after the third dose as measured by an intracellular cytokine staining assay. The estimated duration of this study will be about 4 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: N/A
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
Estimated Study Start Date : September 22, 2021
Estimated Primary Completion Date : July 1, 2025
Estimated Study Completion Date : July 1, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: EBV gp_350 Ferritin Vaccination
Adult participants with or without prior EBV infection will receive 3 doses of vaccine
Biological: EBV gp350-Ferritin Vaccine
A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.

Other: Matrix-M1
Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.




Primary Outcome Measures :
  1. Local and systemic reactogenicity; unsolicited adverse events; serious adverse events; change in neutralizing antibody responses to EBV [ Time Frame: Reactogenicity during the 7-day period after each dose; unsolicited adverse events up to 30 days after each dose; serious adverse events through 1 month after the third dose:; neutralizing antibody response one month after third dose ]
    -Local reactogenicity: pain, tenderness, redness, bruising, swelling; Systemic reactogenicity symptoms: headache, muscle pain, fatigue, chills, oral temperature, joint pain, nausea/ vomiting, diarrhea; Change in log10 antibody response to EBV from baseline to 1 month after third dose of vaccine(Day 210) as measured by neutralization assay.


Secondary Outcome Measures :
  1. Change in antibody responses to EBV gp350; change in CD4+ T cell responses to EBV gp350 [ Time Frame: Change in antibody responses and change in CD4 T cell responses at 1 month after third dose of vaccine ]
    -Change in log10 antibody response to EBV from baseline to 1 month after third vaccine dose measured by a luciferase immunoprecipitation assay; --Change in log10 CD4+ T cell response from baseline to one month after third dose measured by an intracellular cytokine staining assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 29 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. 18 to 29 years old
  2. Screening procedures and evaluations performed no more than 30 days prior to scheduled administration of the first vaccine dose.
  3. Ability of subject to understand and the willingness to sign a written informed consent document.
  4. Stated willingness to comply with all study procedures and availability for the duration of the active phase of the study (approximately 18 months)
  5. Willingness to allow storage of blood and saliva for future research.
  6. In good general health as evidenced by medical history, physical examination, and laboratory screening result.
  7. Subject is willing to forgo receipt of a licensed, live vaccine in the 30 days preceding each dose of vaccine or in the 30 days following each dose of vaccine. An FDA-approved inactivated, subunit or replication-defective flu vaccine and/or a COVID-19 vaccine approved under emergency use authorization can be used >=14 days before or >=14 days after administration of the study vaccine.
  8. For females of reproductive potential who are sexually active with a male partner: use of highly effective continuous contraception for at least 30 days prior to Day 0 and agreement to continue use until 180 days after the last dose of vaccine.
  9. For males who are sexually active with partners of child-bearing potential: use of highly effective continuous contraception from Day 0 and agreement to continue use until 90 days after the last dose of vaccine.

    Contraceptive requirements: Because the effects of EBV gp350-Ferritin vaccine on the developing human fetus are unknown, sexually active female participants of childbearing potential must agree to use highly effective contraception as outlined below before study entry and until 6 months after the last dose of vaccine. Females of childbearing potential must have a negative pregnancy test before receiving each dose of the EBV gp350-Ferritin vaccine. During the course of the study, if a participant becomes pregnant or suspects they are pregnant, then they should inform the study staff and their primary care physician immediately. Acceptable forms of contraception are:

    • Intrauterine device (IUD) or equivalent
    • Hormonal contraceptive (e.g. consistent, timely, and continuous use of contraceptive pill, patch, ring, implant, or injection that has reached full efficacy prior to dosing). If the participant uses a contraceptive pill, path, or ring, then a barrier method (e.g. male/female condom, cap or diaphragm plus spermicide) must also be used at the time of potentially reproductive sexual activity.
    • A stable, long-term monogamous relationship with a partner who does not pose any potential pregnancy risk, e.g. has undergone a vasectomy at least 6 months prior to the first dose of vaccine or is of the same sex as the participant.
    • A hysterectomy and/or a bilateral tubal ligation or bilateral oophorectomy

    Acceptable forms of contraception for male participants include one of the following:

    • Condom plus spermicide, used before or during sexual intercourse, even if the female partner uses a contraceptive pill, patch, or ring
    • A vasectomy completed at least 6 months before the first dose of vaccine
    • Continuously and completely abstaining from sexual intercourse with a female with child-bearing potential from the first dose of vaccine until 3 months after the last dose.

    Acceptable contraception for female partners with child-bearing potential of male study participants include one of the following:

    • IUD or equivalent
    • Hormonal contraceptive (e.g. pill, patch, ring, implant or an injection used consistently and that has reached full effect prior to the first dose of vaccine)
    • Hysterectomy and/or a bilateral tubal ligation or bilateral oophorectomy

    Laboratory Criteria within 30 days or less prior to enrollment:

  10. Hemoglobin within institutional normal limits or if not, then assessed and deemed not clinically significant by PI or designee
  11. White blood cell (WBC) count and differential either within institutional normal reference range or if not then assessed and deemed not clinically significant by PI or designee
  12. Total lymphocyte count (lymphocyte absolute) >= 800 cells/mm3 (0.8 K/mcL)
  13. Platelet count equal to 125,000 500,000/Mm^3 (125-500 K/mcL)
  14. Alanine aminotransferase (ALT) <= 1.25x upper limit of normal (ULN)
  15. Serum IgG > 600 mg/dL
  16. Negative human immunodeficiency virus (HIV) test.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Women who are breastfeeding or planning to become pregnant while participating through 180 days after the last dose of vaccine
  2. Participant has received any of the following:

    1. More than 10 days of systemic immunosuppressive medications (>=10 mg prednisone dose or its equivalent) or cytotoxic medication within the 30 days prior to first dose of vaccine or immunomodulating therapy within 180 days prior to first dose of vaccine.
    2. Blood products, including immunoglobulin products, within 120 days prior to first dose of vaccine
    3. Any live attenuated vaccination within 30 days prior to first dose of vaccine
    4. Medically indicated subunit inactivated or replication-defective vaccines, e.g. influenza, pneumococcal, COVID-19 within 14 days of the first dose of vaccine.
    5. Investigational research agents within 30 days prior to first dose or planning to receive investigational products while on study
    6. Allergy treatment with antigen injections, unless on a maintenance schedule of shots no more frequently than once per month.
  3. Participant has any of the following:

    1. Febrile illness within 14 days of the first dose of vaccine
    2. Body Mass Index (BMI) >36
    3. Serious reactions to vaccines
    4. Hereditary, acquired, or idiopathic forms of angioedema
    5. Idiopathic urticaria within the past year
    6. Asthma that is not well-controlled or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous steroids
    7. Diabetes mellitus type 1 or type 2, excluding a history of gestational diabetes
    8. Clinically significant autoimmune disease or immunodeficiency
    9. Hypertension that is not well-controlled
    10. Thyroid disease that is not well-controlled
    11. Bleeding disorder diagnosed by doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
    12. Significant bruising or bleeding difficulties with IM injections or blood draws
    13. Malignancy that is active or treated malignancy for which there is no reasonable assurance of sustained cure or malignancy that is likely to recur during the study period
    14. Seizure disorder other than a history of 1) febrile seizures 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the past 3 years
    15. Asplenia, functional asplenia or any condition resulting in absence or removal of the spleen.
    16. History of Guillain-Barre Syndrome
    17. Alcohol or drug abuse or addiction
  4. Any medical, psychiatric, or social condition that, in the judgement of the investigator, is a contraindication to protocol participation or impairs the participant s ability to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04645147


Contacts
Layout table for location contacts
Contact: Kayla D Morgan (301) 761-5671 kayla.morgan@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey I Cohen, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04645147    
Other Study ID Numbers: 210005
21-I-0005
First Posted: November 27, 2020    Key Record Dates
Last Update Posted: September 17, 2021
Last Verified: September 1, 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Infectious Mononucleosis
Neutralizing Antibody
CD4+ T cell response
Immune Response
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Epstein-Barr Virus Infections
Infectious Mononucleosis
Virus Diseases
Herpesviridae Infections
DNA Virus Infections
Tumor Virus Infections
Leukocyte Disorders
Hematologic Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases